Retatrutide (LY3437943) is an investigational once-weekly subcutaneous GLP-1/GIP/glucagon agonist. It has shown significant improvements in glycaemic control for people with T2DM and substantial weight reduction in those with obesity. Its safety profile is consistent with other incretin mimetics, making it a promising therapy. The primary patent on retatrutide has been granted so far in at least 16 LMICs, including India, and pending in another 30 LMICs with an expected expiry in 2038.

Acronyms & abbreviations list